Recent randomized trials focused on gene expression-based determination of the cell of origin in diffuse large B-cell lymphoma could not show significant improvements by adding novel agents to standard chemoimmunotherapy. The aim of this study was the identification of a gene signature able to refine current prognostication algorithms and applicable to clinical practice. Here we used a targeted gene expression profiling panel combining the Lymph2Cx signature for cell of origin classification with additional targets including MYC, BCL-2 and NFKBIA, in 186 patients from 2 randomized trials (discovery cohort) (NCT00355199 and NCT00499018). Data were validated in 3 independent series (2 large public datasets and a real-life cohort). By integrating the cell of origin, MYC/BCL-2 double expressor status and NFKBIA expression, we defined a 3-gene signature combining MYC, BCL-2 and NFKBIA (MBN-signature), which outperformed the MYC/BCL-2 double expressor status in multivariate analysis, and allowed further risk stratification within the germinal center B-cell/unclassified subset. The high-risk (MBN Sig-high) subgroup identified the vast majority of double hit cases and a significant fraction of Activated B-Cell-derived diffuse large B-cell lymphomas. These results were validated in 3 independent series including a cohort from the REMoDL-B trial, where, in an exploratory ad hoc analysis, the addition of bortezomib in the MBN Sig-high subgroup provided a progression free survival advantage compared with standard chemoimmunotherapy. These data indicate that a simple 3-gene signature based on MYC, BCL-2 and NFKBIA could refine the prognostic stratification in diffuse large B-cell lymphoma, and might be the basis for future precision-therapy approaches.
A 3-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma / E. Derenzini, S. Mazzara, F. Melle, G. Motta, M. Fabbri, R. Bruna, C. Agostinelli, A. Cesano, C.A. Corsini, N. Chen, S. Righi, E. Sabattini, A. Chiappella, A. Calleri, S. Fiori, V. Tabanelli, A. Cabras, G. Pruneri, U. Vitolo, A.M. Gianni, A. Rambaldi, P. Corradini, P.L. Zinzani, C. Tarella, S. Pileri. - In: HAEMATOLOGICA. - ISSN 0390-6078. - (2020). [Epub ahead of print]
Titolo: | A 3-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma |
Autori: | MAZZARA, SAVERIA (Secondo) TARELLA, CORRADO (Penultimo) |
Parole Chiave: | BCL-2; Diffuse Large B-cell Lymphoma; Gene expression profiling; MYC; NFKBIA; |
Settore Scientifico Disciplinare: | Settore MED/15 - Malattie del Sangue |
Data di pubblicazione: | 2020 |
Rivista: | |
Tipologia: | Article (author) |
Data ahead of print / Data di stampa: | 13-ago-2020 |
Digital Object Identifier (DOI): | http://dx.doi.org/10.3324/haematol.2019.236455 |
Appare nelle tipologie: | 01 - Articolo su periodico |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
haematol.2019.236455.full.pdf | Publisher's version/PDF | Open Access Visualizza/Apri |